A Baltimore clinic setting, a bronze chalice and a capsule of crystalline psilocybin marked the start of an experimental attempt to address persistent symptoms after Lyme disease for Elizabeth Richwine, according to a Sept. 22, 2026 report.
A patient, Elizabeth Richwine, received a psilocybin capsule in a Baltimore medical-office setting as part of an experimental treatment for Lyme disease symptoms.
The report describes the setting and the moment the dose was administered, but does not provide clinical results, trial design details, or broader evidence for psilocybin as a Lyme therapy.
The account appeared on Addiction/Recovery eBulletin on Sept. 22, 2026 and was reported by Robert Bowman.
# What the story says The article describes a single, detailed moment: in a Baltimore medical-office room—a tan couch and nondescript art—a doctor handed patient Elizabeth Richwine an ornate bronze chalice holding a capsule of crystalline psilocybin. The dose was framed as an experimental step toward treating persistent symptoms attributed to Lyme disease.
# Who and when The piece is dated Sept. 22, 2026 and credited to Robert Bowman on Addiction/Recovery eBulletin. The patient named in the account is Elizabeth Richwine. The location is described as a medical office building in Baltimore.
# What actually happened in the encounter The narrative centers on the administration of a single capsule containing psilocybin, the active compound in "magic mushrooms." The story emphasizes the ordinary clinical setting and the unusual ritual of presenting the capsule in a bronze chalice. The account is observational and descriptive about the scene at the time of dosing.
# What the story does not provide The report does not include clinical data, outcome measures, trial protocols, or systematic evidence that the psilocybin dose improved or changed Lyme-related symptoms. It does not describe patient history, inclusion criteria, safety monitoring, follow-up results, or whether this was part of an institutional study, a private clinic procedure, or an approved clinical trial.
# How to read this account This is a single, narrative description focused on a single person's experience at the moment of treatment. It serves as an anecdotal snapshot rather than a clinical report. Readers seeking evidence about psilocybin's efficacy for Lyme disease should look for peer-reviewed studies, trial registrations, or formal safety and outcome reports, none of which are provided in this account.
# Relevant context and nearby coverage
# Practical takeaways for a reader
# Next steps for readers who want more Seek the original article in Addiction/Recovery eBulletin for direct wording and possible follow-up reporting. Search clinicaltrial registries and medical literature for trials of psilocybin or other psychedelics in post-Lyme conditions to find systematic evidence and trial outcomes.
A compound found in the psychedelic plant brew ayahuasca — originating from the Amazon rainforest — was shown to protect dopamine-producing nerve cells and ease movement problems in a mouse model of Parkinson’s disease. A new study by researchers in Spain found that the compound, called N,N-dimethyltryptamine (DMT), al
Molecular autopsy reveals features linked to hallucinations and therapeutic benefits. LSD, a psychedelic drug being studied for its ability to help nerve cells grow and strengthen their connections, has a complicated molecular structure. Researchers at the University of California, Davis have pared that structure down,
After months of headaches and visual hallucinations, a woman was finally revealed to have brain cysts filled with tapeworm larvae
The psychedelic compound that makes magic mushrooms so trippy shows serious promise for protecting cancer patients from years of chronic pain. For people undergoing cancer treatment, the nerve pain associated with blasting the body with chemotherapy can be debilitating. Even worse, the pain and discomfort can last for
What happens when treating anxiety becomes more about quieting symptoms than understanding what is driving them?
ART = HEALTH – August 2026 – When Tara Baggendorf first entered the Aboriginal Drug and Alcohol Council (ADAC) rehabilitation facility in Whitmore Square, Adelaide just under two years ago, she had very little understanding of how addiction could appear in its various forms. As someone who was experiencing alcohol addi
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.